Chemotherapy regimens have been combined with anti-programmed cell death-1 (anti–PD-1) antibodies to enhance the antitumor efficacy of ICB in multiple tumor types with low programmed cell death ligand1 (PD-L1) expression (8, 9). Here, PDCD1 is linked to neoplasm.